These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35861825)

  • 1. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients.
    Schiele F; Quignot N; Khachatryan A; Gusto G; Villa G; Kahangire D; Chauny JV; Ricci L; Desamericq G
    Int J Cardiol; 2021 Jun; 332():22-28. PubMed ID: 33705845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
    Svensson MK; Sorio Vilela F; Leósdóttir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
    Ups J Med Sci; 2022; 127():. PubMed ID: 35722183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany.
    Ahrens I; Khachatryan A; Monga B; Dornstauder E; Sidelnikov E
    Adv Ther; 2021 May; 38(5):2532-2541. PubMed ID: 33830461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.
    Cordero A; Fernández Olmo R; Badimon L; Santos-Gallego CG; Castellano JM; Fácila L; Rodriguez-Manero M; Bonanad C; Vilahur G; Escribano D; Badimon JJ; González-Juanatey JR
    J Clin Lipidol; 2023; 17(5):602-611. PubMed ID: 37775463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
    Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP
    Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
    Li Z; Gao Y; Lu Q; Yin Z; Zhang S; Zhang W; Sui Y; Xu Y; Li J; Dou K; Qian J; Qiu H; Wu N
    Lipids Health Dis; 2024 May; 23(1):134. PubMed ID: 38715079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
    Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
    BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease.
    Kovach CP; Mesenbring EC; Gupta P; Glorioso TJ; Ho PM; Waldo SW; Schwartz GG
    JAMA Netw Open; 2023 Aug; 6(8):e2329066. PubMed ID: 37638630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
    Sawant S; Wang N
    Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.
    Hess CN; Cannon CP; Beckman JA; Goodney PP; Patel MR; Hiatt WR; Mues KE; Orroth KK; Shannon E; Bonaca MP
    J Am Coll Cardiol; 2021 Jun; 77(24):3016-3027. PubMed ID: 34140105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
    Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
    BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.